MavriX Bio Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

MavriX Bio General Information

Description

Developer of an investigational gene replacement therapy designed for the treatment of Angelman syndrome. The company's platform focuses on translating neurogenetic research into clinical progress by advancing a specialized therapeutic candidate derived from academic breakthroughs in genetic medicine, which includes strategic drug development oversight and specialized laboratory research integration to target rare neurogenetic disorders, enabling the biotechnology sector and the Angelman syndrome community to access clinical trials and innovative medical interventions for improved patient outcomes.

Contact Information

Website
www.mvxbio.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 1875 South Grant Street
  • Suite 700
  • San Mateo, CA
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Vertical(s)
Corporate Office
  • 1875 South Grant Street
  • Suite 700
  • San Mateo, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MavriX Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 01-Jan-2025 Completed Startup
To view MavriX Bio’s complete valuation and funding history, request access »

MavriX Bio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Penn Center for Innovation Accelerator/Incubator
To view MavriX Bio’s complete investors history, request access »

MavriX Bio FAQs

  • When was MavriX Bio founded?

    MavriX Bio was founded in 2024.

  • Where is MavriX Bio headquartered?

    MavriX Bio is headquartered in San Mateo, CA.

  • What industry is MavriX Bio in?

    MavriX Bio’s primary industry is Biotechnology.

  • Is MavriX Bio a private or public company?

    MavriX Bio is a Private company.

  • What is MavriX Bio’s current revenue?

    The current revenue for MavriX Bio is .

  • Who are MavriX Bio’s investors?

    Penn Center for Innovation has invested in MavriX Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process